SGEM#518: What Have You Done for Me Lately – Oseltamivir for Hospitalized Patients?

Date: August 23, 2026 Guest Skeptic: Dr. Roya Caloia is a former EM program director, longtime faculty at Henry Ford Genesys and current interim Associate Medical Director. She is also the Chairperson of the National Clinical Governance Board for US Acute Care Solutions Case: A 62-year-old woman with diabetes and chronic lung disease presents to the emergency department (ED) with five days of fever, cough, myalgias and progressively worsening dyspnea. Her respiratory rate is 34 breaths per minute, oxygen saturation is 82% on room air, and chest imaging shows bilateral air-space disease. Molecular testing is positive for influenza A. Despite supplemental oxygen, she requires high-flow nasal oxygen at 50 L/min with an FiO₂ of 0.60. Following initial fluids, her blood pressure remains low, and norepinephrine is started. She has received no more than one dose of oseltamivir before arrival. The ICU team is contacted, and the question is whether she should receive enteral oseltamivir for five days, ten days, or no influenza antiviral. Background: Influenza season has a way of turning the ED waiting room into a coughing convention. Most patients feel miserable but recover with time and supportive care. The concern is the smaller group at higher risk of complications, or those already sick enough to require hospital admission. That is usually when someone asks the annual question: Should we give Tamiflu? Centers for Disease Control and Prevention (CDC) says: “For hospitalized patients with suspected or confirmed influenza, initiation of antiviral treatment with oral or enterically administered oseltamivir is recommended as soon as possible. Antiviral treatment might be effective in reducing morbidity and mortality in hospitalized influenza patients, especially adults, even if treatment is started more than 48 hours after onset of illness.” For those outside the United States, the World Health Organization (WHO) guideline specifically addresses severely ill and critically ill patients. The WHO guideline recommends oseltamivir for patients with severe influenza and even suggests considering extending treatment from 5 to 10 days in critically ill patients. Oseltamivir, better known by the brand name Tamiflu, is an oral neuraminidase inhibitor active against influenza A and B. It blocks an enzyme the virus uses to release newly formed viral particles from infected cells and spread to other cells. Put another way, oseltamivir tries to stop the flu from going viral (dad joke). The usual adult treatment is 75 mg twice daily for five days, with dose adjustment for renal impairment. The regulatory indication focuses on acute, uncomplicated influenza when treatment starts within 48 hours, but clinical guidelines recommend starting it as soon as possible in hospitalized patients, even when they present later in the illness. The challenge is that a biologically plausible mechanism does not automatically produce a patient-oriented outcome (POO). In otherwise uncomplicated influenza, oseltamivir appears to shorten symptoms by about 17 hours on average. That could mean feeling better Tuesday evening instead of Wednesday morning. It has not convincingly reduced hospital admission in outpatient trials, and it does increase nausea and vomiting. Headache and neuropsychiatric events have also been part of the safety discussion, although the causal relationship for the latter remains uncertain. Tamiflu has also been at the centre of one of medicine’s biggest data-transparency battles [1,2]. Much of the phase III evidence supporting oseltamivir had not been published, and independent Cochrane reviewers spent years trying to obtain the full clinical study reports from Roche, the manufacturer. The BMJ’s Open Data campaign helped keep the pressure on until the reports were eventually released. When the Cochrane team examined the more complete record, the benefits appeared smaller and the harms more apparent [3]. This became a cautionary tale about publication bias and why evidence-based medicine requires access to all the evidence, not just the parts selected for publication. This is not SGEM’s first rodeo when it comes to talking about oseltamivir. SGEM#98: Don’t Stand So Close to Me reviewed neuraminidase inhibitors and concluded that the small reduction in symptom duration needed to be weighed against adverse effects. SGEM#312: Oseltamivir is like Bad Medicine looked at primary-care patients with influenza-like illness and remained unconvinced that routine treatment offered a favourable benefit-to-harm ratio. SGEM#397: Give a Little Bit…of Oseltamivir examined hospitalized children and highlighted how much uncertainty remained because the evidence was observational. Finally, SGEM#409: Same as It Ever Was found no good evidence that routine oseltamivir prevented hospitalization among influenza-positive outpatients. For emergency physicians, the more interesting question is not whether an otherwise healthy outpatient gets off the couch 17 hours earlier. It is whether oseltamivir changes outcomes that matter once influenza becomes severe. Much of the rationale for treating hospitalized patients has historically come from observational evidence, while clinical guidelines have continued to recommend early treatment. That is exactly the kind of gap where guideline momentum, biological plausibility, and patient-oriented evidence need to meet under the SGEM skeptical microscope. Clinical Question: In critically ill patients aged 12 years or older with laboratory-confirmed influenza who require respiratory or cardiovascular organ support, does treatment with oseltamivir improve 90-day survival? Reference: Murthy et al. Oseltamivir for Critically Ill Patients with Influenza: A Randomised Trial. SSRN: https://ssrn.com/abstract=7172531 or http://dx.doi.org/10.2139/ssrn.7172531 Population: Hospitalized patients aged 12 years or older with laboratory-confirmed influenza who were critically ill and receiving at least one of the following: High-flow nasal oxygen at ≥30 L/min and FiO₂ ≥0.40, non-invasive ventilation, invasive mechanical ventilation, or vasopressor or inotrope support Exclusions: Patients who were expected to die within 24 hours and for whom there was no commitment to full support, had received sustained organ support for more than 48 hours, had already received more than one dose of oseltamivir, were planned to receive another influenza antiviral or were considered by the treating clinician not to be suitable for participation. Intervention: Oseltamivir 75 mg enterally twice daily (with renal dose adjustment) assigned for either 5 or 10 days. Comparison: No influenza antiviral treatment. However, some sites did not offer the no-antiviral option because of a lack of local clinical equipoise. Five-day oseltamivir had to remain an available option. Outcome: Primary Outcome: All-cause mortality at 90 days. Secondary Outcomes: Survival time to 90 days, hospital and intensive care unit (ICU) length of stay (LOS), cardiovascular- and overall organ-support-free days, progression to invasive ventilation, ECMO or death, and serious adverse events. Type of Study: A multicentre, international, open-label, multifactorial, Bayesian, response-adaptive platform randomized controlled trial. Authors’ Conclusions: “Treatment with oseltamivir is ineffective and highly likely to increase 90-day mortality in critically ill patients with influenza.” Quality Checklist for Randomized Clinical Trials: (Yes, No or Unsure) The study population included or focused on those in the emergency department. No The patients were adequately randomized. Yes The randomization process was concealed. Yes The patients were analyzed in the groups to which they were randomized. Yes The study patients were recruited consecutively (i.e. no selection bias). Unsure The patients in both groups were similar with respect to prognostic factors. No All participants (patients, clinicians, outcome assessors) were unaware of group allocation. No All groups were treated equally except for the intervention. Unsure Follow-up was complete (i.e. at least 80% for both groups). Yes All patient-important outcomes were considered. Yes The treatment effect was large enough and precise enough to be clinically significant. The point estimate is clinically important, but the magnitude is imprecise. Who funded the trial. The platform had numerous predominantly governmental, academic and philanthropic funders. No oseltamivir manufacturer was named as a funder. The investigators stated that funders had no role in study design, analysis or reporting. Did the authors declare conflicts of interest? We could not find the documents online Results: The analysis included 442 participants: 162 assigned to five days of oseltamivir, 156 to ten days and 124 to no antiviral. They were recruited at 139 sites across 18 countries; only 79 sites offered the no-antiviral option. The Median age was 60 years in each oseltamivir group and 63 years in the no-antiviral group. Approximately 38% to 45% were female, and the median symptom duration before randomization was five days. Approximately 89% had influenza A. At randomization, 33% were receiving high-flow nasal oxygen, 15% non-invasive ventilation and 47% invasive ventilation. Almost half were receiving vasopressors in at least one treatment group. A total of 42% had received one dose of oseltamivir before randomization. Key Result: In critically ill patients with laboratory-confirmed influenza requiring organ support, neither five nor ten days of oseltamivir improved survival compared with no antiviral treatment, and both treatment strategies raised a concerning signal of increased mortality. Primary Outcome: Mortality by 90 days Control 14%, Five-day 20%, and Ten-day 19% Five days: OR 2....